Skip to main content
Premium Trial:

Request an Annual Quote

Quidel Expects Q4 Revenues Above Estimates

NEW YORK (GenomeWeb News) – Quidel today said that it expects to report fourth-quarter revenues of $53 million to $54 million.

That figure is well above Wall Street's consensus estimate for revenues of $43.8 million.

"We saw a sudden and early onset to this year's influenza season," Quidel President and CEO Douglas Bryant said in a statement. "I am pleased, however, with how well we were able to respond to the increased and rapid demand for our flu tests."

He added that in addition to its QuickVue Influenza A+B sales benefitting most from patient visits for influenza-like illness, the firm's Sofia Influenza A+B revenues also were a contributor, with Sofia analyzer placements exceeding internal projections.

In early Friday trade on the Nasdaq shares of Quidel were up 6 percent a $21.24.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.